Monte Rosa Therapeutics, Inc. (GLUE) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth No data.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth No data.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth No data.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth No data.
12/26
2.3 / 5 stars
All 26 Win/Lose results and 94 gray no-data contests shown below
Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
Trailing 1 year (4 quarters): 6 wins, 2 losses, 4 no dataLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/2 |
WinGLUE / S&P 47.11% / 15.20% |
LoseGLUE / S&P -83.86% / 15.00% |
No dataGLUE / S&P / 50.40% |
| 2026-Q11/2 |
WinGLUE / S&P 4.91% / -4.33% |
LoseGLUE / S&P -73.07% / 11.30% |
No dataGLUE / S&P / 27.70% |
| 2025-Q42/2 |
WinGLUE / S&P 111.61% / 2.65% |
WinGLUE / S&P 63.54% / 9.00% |
No dataGLUE / S&P / 13.40% |
| 2025-Q32/2 |
WinGLUE / S&P 64.30% / 8.12% |
WinGLUE / S&P 1112.27% / 4.61% |
No dataGLUE / S&P / 13.45% |
| 2025-Q21/2 |
LoseGLUE / S&P -2.80% / 10.94% |
WinGLUE / S&P 2990.57% / 4.83% |
No dataGLUE / S&P / 10.63% |
| 2025-Q11/2 |
LoseGLUE / S&P -33.14% / -4.27% |
WinGLUE / S&P 14889.38% / 4.98% |
No dataGLUE / S&P / 10.57% |
| 2024-Q41/1 |
WinGLUE / S&P 30.94% / 2.41% |
No dataGLUE / S&P / 5.25% |
No dataGLUE / S&P / 6.15% |
| 2024-Q31/1 |
WinGLUE / S&P 41.71% / 5.89% |
No dataGLUE / S&P / 5.89% |
No dataGLUE / S&P / 6.11% |
| 2024-Q20/1 |
LoseGLUE / S&P -46.95% / 4.28% |
No dataGLUE / S&P / 5.38% |
No dataGLUE / S&P / 5.12% |
| 2024-Q11/1 |
WinGLUE / S&P 24.78% / 10.56% |
No dataGLUE / S&P / 5.71% |
No dataGLUE / S&P / 5.59% |
| 2023-Q41/1 |
WinGLUE / S&P 17.95% / 11.69% |
No dataGLUE / S&P / 6.81% |
No dataGLUE / S&P / 7.78% |
| 2023-Q30/1 |
LoseGLUE / S&P -30.07% / -3.27% |
No dataGLUE / S&P / 7.52% |
No dataGLUE / S&P / -5.03% |
| 2023-Q20/1 |
LoseGLUE / S&P -12.07% / 8.74% |
No dataGLUE / S&P / 9.50% |
No dataGLUE / S&P / -8.57% |
| 2023-Q10/1 |
LoseGLUE / S&P 2.37% / 7.50% |
No dataGLUE / S&P / 10.77% |
No dataGLUE / S&P / -15.69% |
| 2022-Q40/1 |
LoseGLUE / S&P -6.85% / 7.56% |
No dataGLUE / S&P / 11.88% |
No dataGLUE / S&P / -17.99% |
| 2022-Q30/1 |
LoseGLUE / S&P -15.51% / -4.88% |
No dataGLUE / S&P / 13.47% |
No dataGLUE / S&P / -1.41% |
| 2022-Q20/1 |
LoseGLUE / S&P -31.03% / -16.10% |
No dataGLUE / S&P / 13.71% |
No dataGLUE / S&P / 11.04% |
| 2022-Q10/1 |
LoseGLUE / S&P -31.34% / -4.60% |
No dataGLUE / S&P / 15.97% |
No dataGLUE / S&P / 42.23% |
| 2021-Q40/1 |
LoseGLUE / S&P -8.35% / 11.03% |
No dataGLUE / S&P / 15.00% |
No dataGLUE / S&P / 96.40% |
| 2021-Q30/1 |
LoseGLUE / S&P -1.85% / 0.58% |
No dataGLUE / S&P / 10.77% |
No dataGLUE / S&P / 69.42% |
| 2021-Q20/0 |
No dataGLUE / S&P / 8.55% |
No dataGLUE / S&P / 6.58% |
No dataGLUE / S&P / 51.81% |
| 2021-Q10/0 |
No dataGLUE / S&P / 6.17% |
No dataGLUE / S&P / -1.06% |
No dataGLUE / S&P / 7.39% |
| 2020-Q40/0 |
No dataGLUE / S&P / 12.15% |
No dataGLUE / S&P / -3.72% |
No dataGLUE / S&P / -33.42% |
| 2020-Q30/0 |
No dataGLUE / S&P / 8.93% |
No dataGLUE / S&P / -2.04% |
No dataGLUE / S&P / -27.10% |
| 2020-Q20/0 |
No dataGLUE / S&P / 20.54% |
No dataGLUE / S&P / -0.46% |
No dataGLUE / S&P / -27.11% |
| 2020-Q10/0 |
No dataGLUE / S&P / -19.60% |
No dataGLUE / S&P / 3.47% |
No dataGLUE / S&P / -14.75% |
| 2019-Q40/0 |
No dataGLUE / S&P / 9.07% |
No dataGLUE / S&P / 5.36% |
No dataGLUE / S&P / 2.99% |
| 2019-Q30/0 |
No dataGLUE / S&P / 1.70% |
No dataGLUE / S&P / 5.02% |
No dataGLUE / S&P / 0.21% |
| 2019-Q20/0 |
No dataGLUE / S&P / 4.30% |
No dataGLUE / S&P / 6.64% |
No dataGLUE / S&P / 8.65% |
| 2019-Q10/0 |
No dataGLUE / S&P / 13.65% |
No dataGLUE / S&P / 8.12% |
No dataGLUE / S&P / 14.29% |
| 2018-Q40/0 |
No dataGLUE / S&P / -13.52% |
No dataGLUE / S&P / 9.05% |
No dataGLUE / S&P / 18.23% |
| 2018-Q30/0 |
No dataGLUE / S&P / 7.71% |
No dataGLUE / S&P / 10.21% |
No dataGLUE / S&P / 19.06% |
| 2018-Q20/0 |
No dataGLUE / S&P / 3.43% |
No dataGLUE / S&P / 9.03% |
No dataGLUE / S&P / 14.46% |
| 2018-Q10/0 |
No dataGLUE / S&P / -0.76% |
No dataGLUE / S&P / 7.68% |
No dataGLUE / S&P / 12.46% |
| 2017-Q40/0 |
No dataGLUE / S&P / 6.64% |
No dataGLUE / S&P / 7.03% |
No dataGLUE / S&P / 13.82% |
| 2017-Q30/0 |
No dataGLUE / S&P / 4.48% |
No dataGLUE / S&P / 5.68% |
No dataGLUE / S&P / 17.57% |
| 2017-Q20/0 |
No dataGLUE / S&P / 3.09% |
No dataGLUE / S&P / 4.83% |
No dataGLUE / S&P / 17.74% |
| 2017-Q10/0 |
No dataGLUE / S&P / 6.07% |
No dataGLUE / S&P / 3.67% |
No dataGLUE / S&P / 13.32% |
| 2016-Q40/0 |
No dataGLUE / S&P / 3.82% |
No dataGLUE / S&P / 2.09% |
No dataGLUE / S&P / 7.05% |
| 2016-Q30/0 |
No dataGLUE / S&P / 3.85% |
No dataGLUE / S&P / 0.20% |
No dataGLUE / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | GLUE total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 198.33% | 20.78% |
| Annualized return | 198.33% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | GLUE total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -62.07% | 83.14% |
| Annualized return | -17.62% | 12.86% |
10Y · 2021-06-24 to 2026-08-27
| Metric | GLUE total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -32.39% | 319.30% |
| Annualized return | -3.84% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |